AsianScientist (Aug. 26, 2013) – Adimab, LLC, a US-based biotech company specializing in monoclonal and bispecific antibodies, has signed a new partnership with Innovent, a Chinese antibody therapeutics and manufacturing company, for the discovery, development and commercialization of an antibody-based therapeutic program.
“Innovent’s manufacturing and product capabilities are impressive. They have built a remarkable manufacturing infrastructure, and we are confident in their ability to develop attractive programs for the Chinese market,” said Tillman Gerngross, Chief Executive Officer of Adimab. “We are excited to enter into this partnership with one of China’s leading biotechnology companies.”
Under the terms of the Agreement, Adimab will utilize its antibody discovery and optimization platform to identify a fully human therapeutic antibody against a target selected by Innovent. All initial product development, including manufacturing and clinical trials, will be coordinated by Innovent.
Innovent will retain rights for commercialization in China, with royalties owed to Adimab on product sales. Adimab will retain rights for commercialization in the US, Europe and Japan, with royalties owed to Innovent on product sales.
“Adimab is clearly a great strategic partner for Innovent. The speed and the quality of their platform has consistently generated therapeutic programs that are superior to the output from competing technologies,” said Michael Yu, Chief Executive Officer of Innovent. “We feel that combining the Adimab platform with Innovent’s strong development and manufacturing capabilities will help us to rapidly build a strong therapeutic pipeline and commercial presence in China.”
——
Source: Adimab, LLC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
